JPMorgan's top biotech and pharma picks for the second half
CNBC: Investing
JUNE 6, 2025
Developing non-opioid pain drugs is a key focus for the industry, with Vertex Pharmaceuticals recently approving its Journavx Nav1.8 Other names on the list include Regeneron Pharmaceuticals and Bristol Myers Squibb. LLY YTD mountain Eli Lilly stock in 2025.
Let's personalize your content